Want to see BOLD full AI Analyst Report?
BOLD Stock Chart & Stats
$2.57
-$0.09(-3.50%)
At close: 4:00 PM EDT
$2.57
-$0.09(-3.50%)
Day’s Range― - ―
52-Week Range$0.96 - $2.97
Previous CloseN/A
Volume121.47K
Average Volume (3M)178.65K
Market Cap
$63.24M
Enterprise Value-$16.50
Total Cash (Recent Filing)$72.63M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.42
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding22,747,986
10 Day Avg. Volume162,533
30 Day Avg. Volume178,649
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.27
Price to Sales (P/S)0.00
P/FCF Ratio-0.57
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe BBI-355 (CHK1) / BBI-825 (RNR) combo arm in the POTENTIATE trial is open for enrollment, suggesting potential data in 2026.
Efficacy And SafetyCHK1i + RNRi could achieve meaningful efficacy at tolerable exposures, avoiding the tox ceiling that crippled prior CHK1s.
Financial OutlookThe company reported $127mn in cash reiterating runway into 1H28, and expects PoC clinical readouts for both programs within this timeline.
Bears Say
Past Trial LimitationsPrior trials combined a CHK1 inhibitor and subtherapeutic gemcitabine and demonstrated responses in multiple tumor types, but were limited by hematological toxicities.
Price Target ReductionThe company reported a reduction in price target from $5 to $4 per share.
Boundless Bio Inc. News
BOLD FAQ
What was Boundless Bio Inc.’s price range in the past 12 months?
Boundless Bio Inc. lowest stock price was $0.96 and its highest was $2.97 in the past 12 months.
What is Boundless Bio Inc.’s market cap?
Boundless Bio Inc.’s market cap is $63.24M.
When is Boundless Bio Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Boundless Bio Inc.’s earnings last quarter?
Currently, no data Available
Is Boundless Bio Inc. overvalued?
According to Wall Street analysts Boundless Bio Inc.’s price is currently Overvalued.
Does Boundless Bio Inc. pay dividends?
Boundless Bio Inc. does not currently pay dividends.
What is Boundless Bio Inc.’s EPS estimate?
Boundless Bio Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Boundless Bio Inc. have?
Boundless Bio Inc. has 22,747,986 shares outstanding.
What happened to Boundless Bio Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Boundless Bio Inc.?
Currently, no hedge funds are holding shares in BOLD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Boundless Bio Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
BOLD Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 2.2M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $1.2M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-52.50%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-26.29%
Trailing 12-Months
Company Description
Boundless Bio Inc.
Boundless Bio, Inc., a clinical-stage oncology company, focuses on developing innovative cancer therapies aimed at addressing the significant unmet needs of patients with oncogene amplified tumors. Their core strategy involves targeting extrachromosomal DNA (ecDNA). The company's lead product candidate, BBI-355, an orally administered inhibitor of checkpoint kinase 1 (CHK1), is currently in Phase 1/2 clinical trials for patients suffering from oncogene amplified cancers. Additionally, Boundless Bio is advancing BBI-825, another oral inhibitor, this one targeting ribonucleotide reductase (RNR), also in Phase 1/2 clinical development for cancer patients exhibiting resistance gene amplifications. A third initiative, the ecDTx 3 program, is designed to target a kinesin crucial for the cellular segregation mechanism of ecDNA. Incorporated in 2018, the company originally operated as Pretzel Therapeutics, Inc. before adopting the name Boundless Bio, Inc. in July 2019. Its headquarters are situated in San Diego, California.
Technical Analysis
Pluri
―
Collplant Holdings
―
ALX Oncology Holdings
―
Aligos Therapeutics
―
Barinthus Biotherapeutics
―
Ownership Overview
39.13% Insiders
9.23% Mutual Funds
1.17% Other Institutional Investors
47.59% Public Companies and
Individual Investors